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ABSTRACT
Members of the CAP superfamily 
(cysteine-rich secretory proteins, antigen 5, and 
pathogenesis related 1 proteins), also known as 
SCP superfamily (sperm-coating proteins),
have been implicated in many physiological 
processes, including immune defenses, venom 
toxicity, and sperm maturation. Their mode of 
action, however, remains poorly understood. 
Three proteins of the CAP superfamily, Pry1, 
2, and 3 (pathogen related in yeast) are encoded 
in the S. cerevisiae genome. We have 
previously shown that Pry1 binds cholesterol in
vitro and that Pry function is required for sterol 
secretion in yeast cells, indicating that members 
of this superfamily may generally bind sterols 
or related small hydrophobic compounds. On 
the other hand, tablysin-15, a CAP protein from 
the horsefly Tabanus yao, has been shown to 
bind leukotrienes and free fatty acids in vitro.
Therefore, here we assessed whether the yeast 
Pry1 protein binds fatty acids. Computational 
modeling and site-directed mutagenesis 
indicated that the mode of fatty acid binding is 
conserved between tablysin-15 and Pry1. Pry1 
bound fatty acids with micromolar affinity in
vitro and its function was essential for fatty acid 
export in cells lacking the acyl-CoA 
synthetases Faa1 and Faa4. Fatty acid binding 
of Pry1 is independent of its capacity to bind 
sterols and the two sterol- and fatty acid-
binding sites are non-overlapping. These 
results indicate that some CAP family 
members, such as Pry1, can bind different 
lipids, particularly sterols and fatty acids, at 
distinct binding sites, suggesting that the CAP 
domain may serve as a stable, secreted protein 
domain that can accommodate multiple ligand-
binding sites. 
Proteins belonging to the CAP 
superfamily (pfam PF00188), also known as 
SCP (sperm coating proteins), are present in all 
kingdoms of life and they have been implicated 
in a number of different physiological 
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processes, including immune defense in 
mammals and plants, pathogen virulence, 
sperm maturation and fertilization, venom 
toxicity, and prostate and brain cancer. Named 
after the three founding members of this protein 
superfamily the mammalian Cysteine-rich
secretory protein, the insect venom allergen 
Antigen 5, and the plant pathogen-induced 
Pathogenesis-related 1 protein, this 
superfamily comprises more than 8’400 
members in over 1’850 species. Most CAP 
proteins are secreted glycoproteins and they all 
share a common CAP domain of approximately 
150 amino acids, which adopts a unique 
sandwich fold. The structural conservation of 
this domain suggests that CAP proteins exert a 
fundamentally similar function. Their precise 
molecular mode of action, however, has 
remained elusive (1, 2). 
 Several CAP family members have been 
shown to bind lipids, suggesting that lipid-
binding may constitute a conserved mode of 
action of these proteins. Firstly, glioma 
pathogenesis-related 2 protein (GLIPR-
2/RTVP-1/GAPR-1) is the smallest of the 
mammalian CAPs and the one most closely 
related to yeast Pry1 (3, 4). It is remarkable as 
it is thus far the only CAP protein that is not 
secreted (5). Instead, the protein is 
myristoylated and associates with the cytosolic 
surface of the Golgi membrane (6). GLIPR-2 is 
highly expressed in glioblastoma, which 
accounts for over 65% of all human primary 
brain tumors (7–9). The non-myristoylated 
protein binds to the surface of liposomes 
containing negatively charged lipids (10). 
Secondly, tablysin-15, a salivary venom 
allergen of the blood-feeding horsefly, Tabanus
yao, acts as a potent inhibitor of plateled 
aggregation through binding integrins (11). In 
addition, tablysin-15 scavenges eicosanoids as 
well as free fatty acids through binding these 
ligands in a hydrophobic channel, thereby 
inhibiting the proinflammatory action of 
cysteinyl leukotrienes that are released from 
mast cells in the area of the insect bite (12). 
Thirdly, Pry proteins (pathogen related
in yeast), CAP superfamily members from 
Saccharomyces cerevisiae, are required for the 
export of sterols in vivo and purified Pry1 binds 
sterols in vitro (13). The sterol-binding and 
export function of yeast Pry proteins appears to 
be a conserved function of members of the CAP 
protein superfamily since expression of the 
human CAP protein CRISP2 complements the 
defect in sterol export of a yeast mutant lacking 
Pry function, and purified CRISP2 binds sterols 
in vitro (13, 14). The capacity to bind sterols is 
also conserved in SmVal4, a CAP protein from 
the human parasite Schistosoma mansoni, as
well as in PR-1, the founding member of the 
CAP superfamily from plants (15, 16). 
Consistent with the proposed defense function 
of PR-1, sterol sequestration by PR-1 inhibits 
growth of plant pathogenic oomycetes, which 
are auxotrophic for sterols (16). Sterol-binding 
by Pry1 requires a flexible loop containing 
aromatic amino acids, termed the caveolin-
binding motif (17). The CAP domain of the 
yeast Pry1 forms dimers in vitro and sterol 
binding is Mg2+-dependent and requires the 
presence of the aliphatic isooctane side chain 
on the steroid ring (4, 18). 
The observation that tabylsin-15 binds 
leukotrienes and free fatty acids in vitro,
prompted us to assess whether the yeast Pry 
proteins also binds free fatty acids and if so, 
whether this fatty acid-binding is of 
physiological significance in yeast. Here, we 
provide evidence that the lipid-binding pocket 
described for tablysin-15 is conserved in the 
yeast Pry1 and that Pry1 has two independent 
lipid-binding sites: one for sterols and one for 
free fatty acids. Binding and export of free fatty 
acids by Pry1 is important for the survival of 
cells that accumulate high intracellular levels of 
free fatty acids as is the case in double mutants 
lacking the two acyl-CoA synthetases Faa1 and 
Faa4. These results indicate that lipid-binding 
and sequestration constitutes a conserved 
function of different CAP family members and 
thus may constitute a uniform mode of action 
of these proteins.
RESULTS AND DISCUSSION 
The fatty acid binding channel of tablysin-15 in 
conserved in Pry1 
 Tablysin-15 binds leukotrienes as well as 
free palmitic acid by a lipid-binding channel 
formed between the two parallel running 
helices, 1 and 3, and closed at the bottom by 
a much shorter helix 4, which runs 
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perpendicular to helices 1 and 3 (12). To 
examine whether yeast Pry1 could also bind 
fatty acids, we first compared the sequence of 
tablysin-15 to that of other CAP proteins, 
including yeast Pry1 and Pry2. Tablysin-15 and 
Pry1 only share 23% sequence identity. 
However, key residues that constitute this lipid-
binding pocket, but not their spacing, are 
conserved in the analyzed CAP family 
members (Fig. 1A). In particular, valine 227 
and valine 254 of Pry1, are predicted to lay in 
close proximity to the hydrocarbon portion of 
the bound palmitate and to contact the ligand 
from two opposite sites. The structure of 
tablysin-15 and Pry1, while displaying a similar 
fold, do not superimpose well with rmsd of 
4.597Å for all main-atoms. The palmitate 
binding cavity of both proteins, however, 
superimpose reasonably well and reveal a 
conserved position and spacing of the two 
helices, 1 and 3, which together form the 
previously identified fatty acid-binding pocket 
(12) (Fig. 1B). 
Yeast Pry1 binds fatty acids 
 Given that the fatty acid binding pocket 
in Pry1 is conserved at both the sequence- and 
the structural-level, we tested whether Pry1 
indeed binds fatty acids in vitro. Therefore, 
purified hexahistidine-tagged Pry1 was 
incubated with increasing concentrations of 
[3H]-palmitic acid, the protein was separated 
from unbound ligand by ion exchange 
chromatography and the protein-bound ligand 
was quantified. This analysis revealed that Pry1 
bound palmitic acid with a saturable binding 
kinetics and an apparent Kd of 112 μM, which 
is comparable to that of tablysin-15 (Kd of 94 
μM) (Fig. 2A). Palmitate binding by Pry1 was 
specific as it could be competed for by the 
addition of unlabeled palmitate (Fig. 2A, B), 
but not by addition of unlabeled cholesterol 
(Fig. 2C). Correspondingly, binding of [3H]-
cholesterol to Pry1 could not be competed for 
by the addition of unlabeled palmitic acid (Fig. 
2D).
 Unlike Pry1, tablysin-15 did not bind 
free cholesterol in vitro (Fig. 3A). To test 
whether the lack of sterol-binding of tablysin-
15 observed in vitro could also be seen in vivo,
we expressed tablysin-15 in yeast and assayed 
its capacity to export sterols, particularly 
cholesteryl acetate (13, 17). Therefore, cells 
were labelled with [14C]-cholesterol, lipids 
were isolated from the cell pellet and the culture 
supernatant, separated by thin layer 
chromatography and the ratio between intra- 
and extracellular cholesteryl acetate was 
quantified and blotted as an export index. 
Expression of tablysin-15 in cells lacking Pry 
function failed to complement the block in 
sterol export, thus confirming the results of the 
in vitro binding assay (Fig. 3B, C).  
 Taken together, these results indicate 
that Pry1 has at least two independent lipid-
binding sites, the caveolin-binding motif, 
which is required for binding free sterols and 
the hydrophobic binding channel between 
helices 1 and 3, which constitutes the 
binding site for free fatty acids and 
leukotrienes. These two lipid binding sites are 
not connected with each other in the structure 
of the CAP domain of Pry1 (4). In addition, the 
results indicate that sterol binding is not a 
universally conserved function of CAP family 
members, as tablysin-15 is the first CAP 
protein found that does not bind sterols in both 
the in vitro and the in vivo assay. Similarly, 
fatty acid-binding may not be a universally 
conserved feature of CAP family members, as 
suggested by the fact that the venom antigen 
Ves v 5 from wasp, does not show a 
hydrophobic channel in its structure (12, 19).  
Mutations in the fatty acid-binding pocket of 
Pry1 affect palmitate-binding  
 To confirm that the hydrophobic pocket 
formed by helices 1 and 3 is indeed the 
palmitate-binding site of Pry1, we generated 
point-mutant versions in which key residues of 
the binding pocket were mutated. As expected 
from structural modeling, substitution of lysine 
173 by tyrosine or that of valine 227 by alanine 
(as found in GAPR1) had only a slight impact 
on fatty acid-binding (Fig. 4A). Instead, the 
exchange of valine 254 by methionine and the 
double substitution of both valine 227 by 
alanine and valine 254 by methionine strongly 
reduced palmitic acid binding of Pry1. The fact 
that the double mutation does not result in a 
further decrease of palmitate binding compared 
to the single substitution of valine 254 by 
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methionine indicates that the valine at position 
254 is most crucial for fatty acid binding.  
 To examine whether these substitutions 
in the fatty acid-binding-pocket, which are only 
few residues away from the flexible loop that is 
required for cholesterol binding, the caveolin-
binding motif contained in residues 236-248 of 
Pry1, we examined in vitro cholesterol binding 
by these mutant versions of Pry1. Cholesterol 
binding was not affected by the substitutions at 
positions 173 and only slightly affected by the 
mutations at residue 227 (Fig. 4B). In contrast, 
the exchange of valine 254 by methionine and 
the double substitution at positions 227 and 
254, reduced the cholesterol-binding affinity of 
Pry1 by more than 6-fold. Since valine 254 is 
buried in the core of the protein, its substitution 
by methionine might impact the overall 
stability of the protein and this might explain 
the observed slight reduction in sterol binding. 
Mutations in the sterol-binding motif of Pry1 do 
not affect palmitate-binding 
 To confirm that the two lipid-binding 
sites on Pry1 are distinct, we tested whether 
mutations in the caveolin-binding motif, which 
affect binding of cholesteryl acetate, would also 
affect the binding of palmitic acid. Mutant 
versions of Pry1 containing an exchange of 
alanine at position 292 by cysteine or that of 
phenylalanine at position 239 by leucine, which 
have previously been shown to affect 
cholesteryl acetate-binding (Fig. 5B) (17), still 
bind palmitic acid with wild-type efficiency 
and binding could be competed for by the 
addition of unlabeled palmitic acid (Fig. 5A). 
These data thus support the notion that the two 
lipid binding sites on Pry1 are distinct and that 
they act independent of each other. 
Pry1 preferentially binds saturated long-chain 
fatty acids 
 To probe the substrate specificity of the 
fatty acid-binding pocket, we performed in
vitro competition binding assays with different 
types of fatty acids. Oleic (C18:1), palmitoleic 
(C16:1), or myristoleic acid (C14:1) competed 
less well for binding than their saturated 
counterparts, stearic- (C18:0), palmitic- 
(C16:0), or myristic acid (C14:0), indicating 
that binding of saturated acyl chains is 
preferred over that of 9- unsaturated ones 
(Fig. 6). Moreover, binding of medium- (C12 
and C14) and long-chain saturated fatty acids 
(C16, C18, C20, and C22) was preferred over 
that of short chain fatty acids (C8 and C10) 
since both caprilic (C8) and decanoic (C10) 
fatty acids essentially failed to compete with 
[3H]-palmitic acid for binding to Pry1 whereas 
the medium chain (C12, C14), the long-chain 
(C16, C18, C20), and even the very long-chain 
fatty acids (C22) competed efficiently (Fig. 6).
 To assess the importance of the carboxyl 
group, we also tested binding of the 
corresponding fatty alcohols. Except for the 
short chain alcohols (C8, and C10), all the 
tested medium-, long-, and very long-chain 
alcohols competed efficiently with [3H]-
palmitic acid for binding to Pry1 (Fig. 6). These 
data thus indicate that fatty acid binding 
requires a minimal chain length of more than 10 
carbon atoms, that kinks in the chain, as 
introduced by a single cis-double bond, are not 
tolerated, and that the carboxyl group is less 
important and can be replaced by a primary 
alcohol.
 Given that tablysin-15 binds arachidonic 
acid (C20:4) and leukotrienes, we also tested 
whether the addition of arachidonic acid 
(C20:4) or that of the cysteinyl leukotriene 
LTC4 would compete for palmitate-binding. 
While the polyunsaturated arachidonic acid 
effectively competed for binding to Pry1, LTC4 
did not (Fig. 6). These results thus indicate that 
Pry1 can bind polyunsaturated fatty acids, such 
as arachidonic acids (C20-5,8,11,14), which 
has its second double bond at position 8 of the 
acyl chain. Mono unsaturated fatty acids, on the 
other hand, contain their double bond at 
position 9 of the acyl chain and do not bind to 
Pry1. LTC4, on the other hand, is composed of 
an arachidonic acid that is contains a 
glutathione modified cysteinyl group. The 
observation that arachidonic acid, but not LTC4 
binds to Pry1, suggests that the presence of the 
glutathione modified cysteinyl group interferes 
with its binding to Pry1.
Pry1 is required for export of fatty acids in vivo 
 To examine whether fatty acid-binding 
by Pry1 is of physiological significance, we 
tested whether Pry1 is required for the export of 
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fatty acids from cells that accumulate high 
levels of free fatty acids. Faa1 and Faa4 are two 
of at least 5 different acyl-CoA synthetases 
present in yeast and they are required for CoA 
activation of exogenous fatty acids (20). 
Mutants lacking the two acyl-CoA synthetases 
Faa1 and Faa4 have previously been shown to 
secrete free fatty acids into the culture medium 
(21, 22). To test whether Pry proteins are 
required for the export of fatty acids from faa1
faa4 double mutant cells, we deleted each one 
of the three PRY genes in an faa1 faa4
double mutant background and quantified the 
levels of free fatty acids secreted from these 
cells into the culture medium. The results of 
this analysis confirm that faa1 faa4 double 
mutant cells have greatly elevated levels of 
fatty acids in the medium when compared to 
wild-type cells (Fig. 7A). Deletion of any one 
of the three Pry proteins, however, did not 
affect the levels of the secreted fatty acids. In 
contrast, double deletion of two of the Pry 
proteins, resulted in a marked decrease of the 
levels of the exported fatty acids, indicating that 
Pry proteins function redundantly in the export 
of fatty acids as they do in the export of 
cholesteryl acetate (Fig. 7B) (13).
 Next, we tested whether mutations in the 
caveolin-binding motif or those in the fatty acid 
binding pocket affect the export of fatty acids. 
In agreement with the in vitro binding results, 
the mutations in the caveolin-binding motif did 
not affect the export of fatty acids by Pry1 (Fig. 
7C). The mutations in the fatty acid binding 
pocket, valine 254 methionine, however, 
reduced the levels of exported fatty acids back 
to background levels, i.e., levels observed in 
cells lacking Pry function. 
Pry function is essential for the viability of cells 
that accumulate free fatty acids 
 Given that the deletion of two of the 
three Pry proteins greatly reduced free fatty 
acid exported in faa1 faa4 mutant cells, but 
did not completely block fatty acid export, we 
wondered whether deletion of the third PRY
gene would further reduce levels of exported 
fatty acids or whether it would render cells non-
viable. To test this, we generated faa1 faa4
double mutant cells, carrying a rescuing 
plasmid containing FAA1, and lacking either 
two or all three of the PRY genes. We then 
tested whether the rescuing pFaa1 plasmid, 
which was marked by URA3, could be lost by 
strains lacking two of the PRY genes (pry1
pry2) or all three of them (pry1 pry2
pry3). While cells lacking only two of the 
three PRY genes could lose the plasmid borne 
copy of FAA1, as indicated by their growth on 
media containing 5-fluoroorotic acid (5-FOA), 
which selects for cells that are uracil auxotroph, 
cells lacking all three PRY genes failed to grow 
on 5-FOA medium, indicating that PRY
function becomes essential in cells lacking the 
acyl-CoA synthetases Faa1 and Faa4 (Fig. 8A).  
 Since Pry1 binds fatty acids in vitro and 
Pry function is required for the export of fatty 
acids in cells that are impaired in CoA 
activation of free fatty acids, we wondered 
whether Pry function is required for the export 
of these free fatty acids from cells. If this were 
the case, one would expect that the levels of 
intracellular fatty acids would increase upon 
depletion of Pry function. To test this, we 
generated a strain in which the transcription of 
PRY1 could be shut off through a switch in 
carbon sources. Cultivation of this strain, 
bearing a plasmid borne copy of PRY1 under 
control of a galactose inducible and glucose 
repressible promoter, in a background lacking 
genomic Pry function as well as the two acyl-
CoA syntheases (pGAL-PRY1 pry1 pry2
pry3 faa1 faa4), in glucose media resulted 
in a time-dependent increase of intracellular 
free fatty acids (Fig. 8B). When cultivated in 
galactose containing media, on the other hand, 
the levels of intracellular fatty acids remained 
on a constant low level. Under these conditions, 
about 90% of the free fatty acids were exported 
from the cells, whereas under repressible 
conditions, that is in glucose media, the fatty 
acid export index (the fraction of exported fatty 
acid divided by the sum of extracellular and 
intracellular fatty acids) displayed a time-
dependent decline, reaching a minimum of 40% 
of fatty acids exported after cultivation for 24 
hours in glucose media (Fig. 8C). These data 
thus indicate that the levels of exported fatty 
acids correlate with the steady-state levels of 
Pry1 protein and, given that Pry1 is a secreted 
glycoprotein (13), they support the notion that 
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fatty acids are exported from cells as complexes 
bound to Pry1.
 Since high levels of intracellular fatty 
acids are toxic (23–26), the marked increase of 
intracellular fatty acids in cells depleted of Pry1 
is likely to explain the non-viability of cells 
lacking all Pry function in a faa1 faa4
mutant background. Consistent with this 
notion, growth of these cells was rescued by 
sublethal doses of cerulenin, an inhibitor of 
fatty acid synthesis (27) (Fig. 8D).
 Taken together, the data presented in this 
study indicate that the yeast CAP superfamily 
member, Pry1, and possibly many other CAP 
family members, can bind and thereby 
scavenge at least two different types of lipid, 
sterols and fatty acids. In yeast, both these lipid 
binding functions of the Pry proteins are of 
physiological importance as they become 
essential under specific growth condition. 
Sterol-binding is important to secrete modified 
sterols, such as cholesteryl acetate, and 
required for growth in the presence of eugenol, 
a plant derived antimicrobial compound that 
binds to the caveolin-binding motif of Pry1, 
and whose toxic action is thereby neutralized 
(13, 18). For the antimicrobial defense of 
plants, on the other hand, scavenging of sterols 
by PR-1 is likely important to inhibit the growth 
of sterol auxotrophic pathogens, such as 
oomycetes (16). Fatty acid binding, on the other 
hand, is required for the growth of yeast cells 
under conditions of elevated levels of 
intracellular free fatty acids, as occurs in 
mutants lacking major acyl-CoA synthetase, 
but is presumably also important in cells having 
reduced synthesis or uptake of CoA itself, or 
those displaying enhanced lipid remodeling 
induced by membrane perturbing agents. Insect 
venom antigens of the CAP superfamily, on the 
other hand, may employ this hydrophobic 
binding channel to scavenge and sequester 
immune modulators of their hosts, as 
exemplified by the leukotriene binding of 
tablysin-15 (12). The key question, of course is, 
what is the uniform function of the conserved 
CAP domain? Is it the three-dimensional 
structure of the domain that is of functional 
importance, as is commonly the case for 
proteins? Alternatively, the CAP domain with 
its unique fold might serve as a stable and 
secreted scaffold into which different types of 
hydrophobic binding pockets can be 
implemented. The secreted CAP domain 
containing proteins could thus act to scavenge 
and neutralize the action of small hydrophobic 
compounds that these proteins encounter in 
their specific physiological setting. This ligand 
binding CAP domain could then be further 
functionalized by the addition of auxiliary 
modules, such as the Arg-Gly-Asp (RGD) 
motif, which is present in tablysin-15 and binds 
integrins (11), or the potassium ion channel 
inhibitor-like fold, which is present in the 
cysteine-rich domain (CRD) of Stecrisp and the 
mouse testis specific protein 1 (Tpx-1) (28, 29). 
EXPERIMENTAL PROCEDURES 
Yeast strains, growth conditions and epitope 
tagging, and site-directed mutagenesis 
 Yeast mutant strains were cultivated 
either in rich media, YPD (containing 1% Bacto 
yeast extract, 2% Bacto peptone, and 2% 
glucose, US Biological Swampscott, MA), in 
YPGal containing 2% galactose instead of 
glucose, or in minimal defined media 
(containing 0.67% yeast nitrogen base without 
amino acids (US Biological), 0.73g/l amino 
acids, and 2% glucose). Media supplemented 
with sterols and fatty acids contained 0.05 
mg/ml Tween 80 and 20 μg/ml cholesterol 
(Sigma Chemical Co., St Louis, MO). To 
bypass heme deficiency, cells were grown in 
media supplemented with 10 μg/ml delta-
aminolevulinic acid. To counterselect for the 
presence of URA3 containing plasmids, 5-
fluoroorotic acid (5-FOA; bts BioTech Trade 
and Service Gmbh, St. Leon-Rot, Germany) 
was added to solid media at 1 g/l. Mutant strains 
were generated by gene disruption using PCR 
deletion cassettes and a marker rescue strategy 
(30). Cerulenin (Sigma Aldrich, St. Louis, MO) 
was diluted in DMSO and used from a 1,000×
stock. For growth analysis, strains were diluted 
tenfold and diluted samples were spotted onto 
plates supplemented with the appropriate 
medium. Plates were grown for 3 days at 30°C 
and were then photographed. Growth curves 
were recorded using a Bioscreen C MBR (Oy 
Growth Curves Ab Ltd., Helsinki, Finland). 
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Expression and purification of tablysin-15 and 
Pry1
 For in vivo lipid export assays, DNA 
encoding tablysin-15 was synthesized 
(GenScript, Piscataway, NJ), PCR amplified 
and cloned into a pGREG506-based plasmid in 
which the GAL promoter was replaced by an 
ADH promoter and the proteins were fused to 
the Pry1 ER signal sequence, amino acids 1–19 
(13). Wild-type and mutant versions of Pry1 
were PCR amplified and cloned into the NcoI
and XhoI sites of pET22b vector (Novagen, 
Merck, Darmstadt, Germany), which contains a 
PelB signal sequence to direct the secretion of 
the expressed protein into the periplasmic 
space. Similarly, Plasmids were transformed 
into Escherichia coli BL21 and the proteins 
were expressed as a poly histidine-tagged 
fusion after lactose induction and overnight 
growth of the bacteria at 24°C. Cells were 
harvested, lysed, and incubated with Ni-NTA 
beads (Qiagen, Hilden, Germany) as per 
instructions of the manufacturer. Beads were 
washed and proteins were eluted with 
imidazole, concentrated and quantified. Protein 
concentration was determined by Lowry assay 
using Folin reagent and BSA as standard. 
Lipid labeling and analysis 
Acetylation and export of sterols into the 
culture media was examined as described 
previously (31). Yeast mutants deficient in 
heme biosynthesis (hem1) were cultivated in 
presence of Cholesterol/Tween-80 and labeled 
with 0.025 μCi/ml [14C]-cholesterol (American 
Radiolabeled Chemicals Inc, St. Louis, MO). 
Cells were harvested by centrifugation, washed 
with SC media, diluted to an OD600 of 1 into 
fresh media containing non-radiolabeled 
cholesterol and grown overnight. Cells were 
centrifuged and lipids were extracted from the 
cell pellet and the culture supernatant using 
chloroform/methanol (1:1; per vol.). Samples 
were dried and separated by thin-layer 
chromatography on silica gel 60 plates (TLC; 
Merck, Darmstadt, Germany) using the solvent 
system, petroleum ether/diethylether/acetic 
acid (70:30:2; per vol.). TLC plates were 
exposed to phosphorimager screens and 
radiolabeled lipids were visualized and 
quantified using a phosphorimager (GE 
Healthcare, Pittsburgh, PA). 
Fatty acid quantification 
Fatty acid methyl esters (FAMEs) were 
prepared from 5 OD600 units of yeast cells. 
Wild-type and mutant cells were grown in 
synthetic complete (SC) medium at 30°C. Cells 
were washed once in cold water, and a fatty 
acid standard (C17:0; 50 μg; Sigma) was 
added. Cells were disrupted using glass beads, 
and lipids were extracted using 
chloroform/methanol (1:1; per vol.) for cellular 
lipids and chloroform/methanol/conc. HCl 
(1:2:0.03; per vol.) for extracellular fatty acids. 
FAMEs were produced using boron trifluoride 
at 100°C for 45 min and were recovered by 
extraction with petrol ether. After evaporation, 
extracts were resuspended in hexane. FAMEs 
were separated with an Agilent 7890A gas 
chromatograph (GC) equipped with a DB-23 
capillary column (30 m x 0.25 mm x 0.25 μm; 
Agilent Technologies, Santa Clara, CA). The 
temperature of the injection port was set to 
250°C, its pressure to 26.24 lb/in2 (average 
velocity, 48.17 cm/s), and the septum purge 
flow to 3 ml/min. Split injections occurred 
through an Agilent 7693A automated liquid 
sampler. The initial oven temperature (100°C; 
held for 2 min) was increased to 160°C at the 
rate of 25°C/min and was then increased again 
to 250°C at 8°C/min. The final oven 
temperature was held for an additional 4 min. 
FAMEs were detected with a flame ionization 
detector (Agilent Technologies) set at 270°C 
with H2, air, and He flows set at 30, 400, and 
27.7 ml/min, respectively. FAMEs were 
quantified relative to the internal standard, and 
the relative response factor for each FAME was 
determined from a 4-level calibration curve (r2,
0.999).
In vitro lipid binding assay 
The radioligand binding assay was 
performed as described previously (13, 32). 
Purified protein (100 pmol) in binding buffer 
(20 mM Tris, pH 7.5, 30 mM NaCl, 0.05% 
Triton X-100) was incubated with [3H]-
cholesterol (50 pmol) or [3H]-palmitic acid for 
1 h at 30°C. The protein was then separated 
from the unbound ligand by adsorption to Q-
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sepharose beads (GE healthcare, USA), beads 
were washed and the protein-bound radioligand 
was quantified by scintillation counting. For 
competition binding assays, unlabeled 
cholesterol, palmitic acid (50 pmol), saturated 
and mono-unsaturated fatty acids, fatty 
alcohols, arachidonic acid (all from Sigma 
Chemical Co., St Louis, MO), or LTC4 (Avanti 
polar lipids, Alabaster, AL) were included in 
the binding reaction. To determine non-specific 
binding, the binding assay was performed 
without the addition of the protein. Statistical 
significance of data was analyzed by a multiple 
t-test (GraphPad Prism, La Jolla, CA). 
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FIGURE LEGENDS 
FIGURE 1. The palmitate-binding site of tablysin-15 is conserved in yeast Pry1.  
A) A multiple sequence alignment limited to the residues important for palmitic acid binding of 
tablysin-15 with taxonomically diverse CAP family members is shown. Sequences from the 
following CAP family members with their UniProt identifier given in the parentheses were aligned: 
horsefly tablysin-15 (F8QQG5), wasp venom allergen 5 (VA5, Q05110), Naja atra natrin-1 
(CRVP1, Q7T1K6), tomato PR1B1 (P04284), human GLIPR2/GAPR1 (Q9H4G4), yeast Pry1 
(P47032), yeast Pry2 (P36110). Key residues shown in colors are those forming the fatty acid 
binding site in tablysin (12). Those shown in green and orange are those that were mutated. B) 
Comparison of the structure of the fatty acid binding pocket of tablysin-15 to that of yeast Pry1. 
The structures of the two proteins around the fatty acid binding pocket are superimposed with 
tablysin-15 in blue and Pry1 in grey with the bound palmitic acid shown in magenta. Key residues 
lysine 173, valine 227, and valine 254 are indicated. 
FIGURE 2. Yeast Pry1 binds palmitic acid. 
A) Comparison of the in vitro palmitic acid binding affinities of tablysin-15 and Pry1. Purified 
tablysin-15 and Pry1 (100 pmol) were incubated with the indicated concentration of [3H]-palmitic 
acid in the presence (Pry1 + 400 pmol Pal) or absence of unlabelled competitor ligand (Tablysin, 
Pry1). The protein was separated from the unbound ligand by adsorption to an anion-exchange 
matrix and the protein-bound radioligand was quantified by scintillation counting. B) Unlabelled 
palmitic acid competes with [3H]-palmitic acid for binding to Pry1. Binding of [3H]-palmitic acid 
(50 pmol) to Pry1 (100 pmol) was assessed in the presence of the indicated concentration of 
unlabeled palmitic acid (Pal). The first bar shows background values obtained in the absence of 
added protein. C) Cholesterol does not compete with [3H]-palmitic acid for binding to Pry1. 
Binding of [3H]-palmitic acid (50 pmol) to Pry1 (100 pmol) was assessed in the presence of the 
indicated concentration of unlabeled cholesterol (Chol). D) Palmitic acid does not compete with 
[3H]-cholesterol for binding to Pry1. Binding of [3H]-cholesterol (50 pmol) to Pry1 (100 pmol) was 
assessed in the presence of the indicated concentration of unlabeled palmitic acid (Pal). Values 
represent means ± SD of three independent determinations. Asterisks denote statistical significance 
(** P < 0.001; *** P < 0.0001). n.s., non-significant. 
FIGURE 3. Tablysin-15 does not bind sterols in vitro and fails to complement the sterol export 
defect of cells lacking Pry function. A) Tablysin-15 does not bind sterols in vitro. The indicated 
amount of purified Pry1 or tablysin-15 were incubated with [3H]-cholesterol (50 pmol) and ligand 
binding was quantified. B) Expression of tablysin-15 in pry mutant yeast cells does not rescue the 
block in sterol export. Heme-deficient cells of the indicated genotype expressing tablysin-15 were 
radiolabeled with [14C]-cholesterol. Cells were washed and chased with media containing unlabeled 
cholesterol, lipids were extracted from the cell pellet (P) and the culture supernatant (S), and 
separated by TLC. The positions of free cholesterol (FC), cholesteryl acetate (CA) and that of steryl 
esters (STE) are indicated. The star marks the position of an unidentified cholesterol-derivative. C) 
Quantification of the export of cholesteryl acetate. The export index indicates the relative 
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percentages of cholesteryl acetate that is exported. Data represent mean ±SD of three independent 
experiments. Asterisks denote statistical significance (*** P < 0.0001). 
FIGURE 4. Mutations within the fatty acid binding pocket of Pry1 abrogate binding of fatty acids 
but not that of sterols.
A) Valine 254 is crucial for in vitro binding of palmitic acid by Pry1. The indicated residues in the 
fatty acid binding pocket of Pry1 were mutated and in vitro binding of [3H]-palmitic acid (100 - 
400 pmol) to the wild-type (wt) and mutant versions of Pry1 was assessed. No Kd valused can be 
determined for the V254M single and the V227A V254M double mutant (n.d.) B) Mutations in the 
fatty acid binding pocket do not strongly affect sterol binding by Pry1. The indicated point-mutant 
versions of Pry1 (100 pmol) were incubated with [3H]-cholesterol (100 – 400 pmol) and ligand 
binding was quantified. Values represent means ± SD of three independent determinations. 
FIGURE 5. Mutations in sterol-binding loop of Pry1, the caveolin-binding motif, do not affect in
vitro binding of fatty acids.
A) Pry1 wild-type (wt) and mutant proteins bearing point mutations in the caveolin-binding motif, 
A292C and F239L (100 pmol each), were incubated with [3H]-palmitic acid (50 pmol) in the 
presence or absence of unlabeled palmitic acid (50 pmol) and ligand binding was quantified. B) 
Pry1 wild-type (wt) and mutant proteins bearing point mutations in the caveolin-binding motif (100 
pmol each), were incubated with [3H]-cholesterol (50 pmol) in the presence or absence of unlabeled 
cholesteryl acetate (50 pmol) and binding of the radioligand was quantified. Values represent means 
± SD of three independent determinations. Asterisks denote statistical significance (** P < 0.001). 
FIGURE 6. Pry1 preferentially binds saturated medium- and long-chain fatty acids and fatty 
alcohols.
Ligand binding specificity was tested by a competition binding assay. Pry1 (100 pmol) was 
incubated with [3H]-palmitic acid (50 pmol) in the presence or absence of the indicated unlabeled 
fatty acid (50 pmol), arachidonic acid (C20:4) or the cysteinyl leukotriene LTC4, and binding of 
the radioligand was quantified. The chain length and degree of unsaturation of the tested fatty acids 
and the fatty alcohols (-OH) is indicated. Values represent means ± SD of three independent 
determinations. Asterisks denote statistical significance (** P < 0.001; *** P < 0.0001). n.s., non-
significant (P > 0.02); n.d., not determined. 
FIGURE 7. Fatty acid binding by Pry and tablysin-15 is required for the in vivo export of fatty 
acids from mutant cells lacking the acyl-CoA synthetases, Faa1 and Faa4. 
A) faa1 faa4 double mutant cells export fatty acids even in the absence of one of the three yeast 
Pry proteins. Wild-type (wt) and faa1 faa4 double mutant cells lacking any one of the three Pry 
proteins were cultivated in SC media to 2 OD. Cells were pelleted and the free fatty acids present 
in the culture supernatant were analyzed and quantified by GC-MS. B) Pry double mutant cells 
have a block in export of fatty acids. Cells of the indicated genotype were cultivated in SC media 
and levels of fatty acid exported into the culture supernatant was quantified. C) Mutations in the 
fatty acid binding pocket of Pry1 abrogate the in vivo export of fatty acids. Quadruple mutant cells 
(pry1 pry2 faa1 faa4) carrying a plasmid-borne wild-type copy of tablysin-15, Pry1 or one 
of the indicated point-mutant versions were cultivated in SC media and fatty acids exported into 
the culture supernatant were quantified. Values represent means ± SD of three independent 
determinations. Asterisks denote statistical significance (** P < 0.001; *** P < 0.0001). 
FIGURE 8. Pry function is essential in cells that export fatty acids. 
A) Wild-type, quadruple (pry1 pry2 faa1 faa4), and quintuple (pry1 pry2 pry3 faa1
faa4) mutant cells bearing a plasmid-borne copy of FAA1 (pFaa1) were serially diluted 10-fold 
and stamped on YPD, SC-URA, or 5-fluoroorotic acid (5-FOA) containing solid media. Plates were 
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incubated at 30°C for 3 days. B) Transcriptional shut off of PRY1 results in a time-dependent 
increase of intracellular fatty acids. Quintuple mutant cells (pry1 pry2 pry3 faa1 faa4)
bearing a plasmid-borne copy of PRY1 under the transcriptional control of a galactose-inducible 
promoter (pGal-PRY1) were cultivated in galactose containing media and diluted into fresh media 
containing either glucose (Glu) or galactose (Gal). Cells were cultivated for the indicated period of 
time and intracellular fatty acid levels were quantified by GC-MS. C) Export of fatty acids is 
arrested upon shut off of PRY1 transcription. Cells were cultivated as described for panel B and the 
ratio of extracellular fatty acids to that of the sum of both intra- and extra-cellular fatty acid is 
shown as an export index. D) Blocking fatty acid synthesis rescues growth of cells lacking Pry 
function. Quintuple mutant cells (pry1 pry2 pry3 faa1 faa4) bearing the glucose repressible 
pGal-PRY1 were cultivated in media containing galactose (Gal), glucose (Glu), or glucose and the 
fatty acid synthase inhibitor cerulenin (Cer, 0.1 μg/ml). Cell density over time was recorded using 
a Bioimager. The growth curves shown are representative of three independent experiments. 
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